Highest-materiality recent filing
Biofrontera Q2 revenue up 33% to $12.0M; net loss narrows to $0.6M
Q2 net product revenue $12.0M, up 32.9% YoY; gross margin 80% vs 71% prior year.
Biofrontera Q1 revenue up 17% to $10.1M; gross margin 80%; PDUFA for sBCC set Sept 2026
Revenue $10.1M (+17% YoY); gross margin 80% (vs 62% Q1 2025) from new earnout structure.
Q4 2025 revenue $17.1M, up 36% YoY; net income $5.6M vs. net loss $1.4M in Q4 2024.
Phase 2b study: 3-hour Ameluz incubation achieved 57.97% reduction in inflammatory lesions vs 36.51% for vehicle.
PTAB finds Sun Pharma’s patent '028 unpatentable, a win for Biofrontera in patent dispute
PTAB issued Final Written Decision on Feb 23, 2026, invalidating all challenged claims of Sun's U.S. Patent No. 11,697,028.
Biofrontera Phase 3 Ameluz® PDT meets primary endpoint for AK on extremities/neck/trunk
Complete clearance 45.6% (Ameluz®) vs 16.7% (vehicle), p<0.0003 in FAS.
Biofrontera reports record preliminary Q4 2025 revenue of $17.0-17.5M, up ~35-39% YoY
Q4 2025 preliminary revenue $17.0-17.5M, highest quarterly revenue in history, YoY growth 35-39%.
Biofrontera receives Nasdaq deficiency notice for bid price below $1.00 for 34 days
Nasdaq notice on Dec 31, 2025: common stock not compliant with Listing Rule 5550(a)(2) due to closing bid below $1.00.
Biofrontera Q3 revenue $7.0M, net loss $6.6M; closes Ameluz asset purchase
Q3 2025 revenues $7.0M (down 22% YoY); 9-month revenues stable at $24.6M vs $24.8M.
Biofrontera regains Nasdaq compliance on stockholders' equity and bid price rules
Received Nov 4 notice from Nasdaq confirming compliance with Rule 5550(b)(1) (stockholders' equity).
Biofrontera sells Xepi® license to Pelthos for up to $10M; receives $3M at close
Sold US license of Xepi® (ozenoxacin) cream to Pelthos Therapeutics for up to $10M total consideration.
Biofrontera closes acquisition of U.S. rights to Ameluz; raises $2.5M in Series C preferred
Acquired all U.S. rights to Ameluz and RhodoLED from former parent Biofrontera AG per Asset Purchase Agreement dated Oct 20, 2025.
Biofrontera closes purchase of Ameluz/RhodoLED US assets, reduces earnout to 12-15%
Acquired all U.S. assets and rights to Ameluz and RhodoLED, including NDA, patents, manufacturing, and personnel.
Biofrontera Q2 rev $9.0M (+15%); net loss $5.3M; restructures AG deal, new royalty 12-15%
Q2 2025 revenue $9.0M (up 15% YoY); net loss $5.3M vs $0.3M in Q2 2024.
Biofrontera appoints George Jones as Chief Commercial Officer effective August 25, 2025
George Jones named CCO of Biofrontera (Nasdaq: BFRI), bringing over 25 years of commercial leadership in pharmaceuticals and biotech.
Biofrontera to acquire US Ameluz/RhodoLED rights; royalty 12-15%, 10% equity stake
Upfront EUR 2,593,750 payment due June 30, 2025; condition to raise $8.5M preferred equity by same date.
Acquired all U.S. rights to Ameluz and RhodoLED from Biofrontera AG; will pay royalty of 12% or 15% based on $65M revenue threshold.
Biofrontera acquires US Ameluz/RhodoLED rights, cuts royalty to 12%, gets $11M financing
Acquires all US assets for Ameluz and RhodoLED including NDA and patents from Biofrontera AG.
Biofrontera confirms talks with Biofrontera AG on merger or license restructuring
Negotiations with Biofrontera AG include possible combination of the two companies.
Biofrontera receives Nasdaq deficiency notice for equity below $2.5M
Stockholders' equity at $469,000, well below Nasdaq's $2.5M minimum requirement.
Biofrontera Q1 2025 revenue $8.6M (+9% YoY); net loss narrows to $4.2M
Total revenues $8.6M, +8.7% YoY; net loss $4.2M ($0.47 per share) vs $10.4M ($2.88) prior year.
Biofrontera receives Nasdaq bid price deficiency notice, 180 days to cure
Nasdaq notified Biofrontera on May 8, 2025 that common stock bid price closed below $1.00 for 33 consecutive business days.
Biofrontera reports record FY 2024 revenue $37.3M, up 9.5% YoY; Q4 net loss $1.4M
Record total revenues $37.3M for 2024, +9.5% from $34.1M in 2023; Q4 revenues $12.6M, +18.5% YoY.
Biofrontera issues $4.2M in 10% secured convertible notes due 2027
$4.2M private placement of 10% Senior Secured Convertible Notes due Nov 22, 2027 to principal stockholders.
Biofrontera Q3 revenue $9.0M (+1.5% YoY); net loss narrows; FDA approves higher Ameluz dosage
Total Q3 2024 revenue $9.0M, up 1.5% YoY (would have been +19% without Hurricane Milton delays of ~$1.5M).
Biofrontera reports Phase 3 sBCC study success; Ameluz-PDT primary endpoint met p<0.0001
Primary endpoint: 65.5% complete clearance vs 4.8% placebo (p<0.0001); histological clearance 75.9% vs 19.0%.
FDA approves Biofrontera's sNDA for up to 3 tubes of Ameluz per treatment
FDA increased max dosage from 1 to 3 tubes of Ameluz per PDT treatment for actinic keratosis.
Biofrontera Q2 revenue $7.8M (+34% YoY); net loss narrows to $0.3M from $9.8M
Q2 2024 total revenues $7.8M, up 34% from $5.8M in Q2 2023; catch-up from lower 1Q sales due to Change Healthcare cyber event.
Biofrontera Q1 revenue down 9% to $7.9M; net loss $10.4M; Ameluz license renegotiated
Q1 revenue $7.9M, down 9% YoY from $8.7M due to Change Healthcare data breach reimbursement issues.
Biofrontera achieves milestones on Series B-3 warrants, unlocking $8M gross proceeds
Board certified >5% YoY revenue growth (Jan-Apr 2024 vs 2023, ex-related parties) and >95% CRM adoption.
Biofrontera reports record FY2023 revenue of $34.1M, +19% YoY; Q4 net income $3.5M
FY2023 total revenues $34.1M (+19% YoY); operating expenses $56.7M (incl $2M one-time legal).
$8.0 million raised from Series B-1 Preferred at $1,000/share; warrants for additional $8.0 million upon milestone achievement and shareholder approval.
Biofrontera cuts Ameluz transfer price to 25%, raises up to $16M in private placement
Transfer price reduced from 50% to 25% for 2024-2025; stepwise increases to max 35% from 2032; minimum dollar amount per unit.
FDA accepts Biofrontera sNDA to allow up to 3 tubes of Ameluz per treatment; PDUFA Oct 4, 2024
FDA completed filing review; target action date October 4, 2024 for Ameluz sNDA to increase max dosage from 1 to 3 tubes per treatment.
Biofrontera defers ~$4.3-4.5M payment to Feb 29; warrants exercised for 888K shares
Payment due Jan 31, 2024 deferred to Feb 29, 2024 under amended addendum to license and supply agreement.
Biofrontera gets Nasdaq extension until May 20, 2024 to regain compliance
Nasdaq granted a 180-day extension from Nov 22, 2023 (new deadline May 20, 2024) to regain compliance.
On July 7, 2023, the board of directors (the “Board”) of Biofrontera Inc. (the “Company”) appointed Heikki Lanckriet to the Board.
On May 25, 2023, the Board appointed Hermann Luebbert, the Company’s current Executive Chairman, to succeed Erica Monaco as the Company’s Chief Executive Officer as part of the transition of management responsibilities following the resignation of Ms. Monaco previously reported by the Company.
Ms. Monaco would step down as Chief Executive Officer effective on May 26, 2023
On May 22, 2023, the Company received a letter (the “Resignation Letter”) from Loretta Wedge tendering her resignation as a member of the Board.
Erica Monaco, Chief Executive Officer of the Company notified the Company’s Board of Directors that she intends to resign from the Company to pursue other opportunities.
On October 24, 2022, Biofrontera Inc. (the “Company”) announced that, effective as of that date, Fred Leffler has been appointed as Chief Financial Officer of the Company.
On March 2, 2022, the board of directors (“Board”) of Biofrontera Inc. (the “Company”) voted to increase the size of the Board from four directors to five directors and appointed Kevin D. Weber to fill the vacancy resulting from such increase.
John J. Borer, Beth J. Hoffman, Ph.D, and Loretta M. Wedge, CPA, CCGMA (collectively, the “Directors”) were appointed to the board of directors of the Company
John J. Borer, Beth J. Hoffman, Ph.D, and Loretta M. Wedge, CPA, CCGMA (collectively, the “Directors”) were appointed to the board of directors of the Company
Erica Monaco resigned her position on the board of directors of the Company
John J. Borer, Beth J. Hoffman, Ph.D, and Loretta M. Wedge, CPA, CCGMA (collectively, the “Directors”) were appointed to the board of directors of the Company
Max materiality 0.85 · Median 0.65 · Most common event other_material